Conjunctiva

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on: 
Friday, March 22, 2024

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points: 
  • Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
  • Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
  • Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
  • Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.

New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease

Retrieved on: 
Friday, April 5, 2024

“Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.

Key Points: 
  • “Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.
  • As ophthalmologists, we need to listen closely to our patients and coordinate with optometrists to fully understand the impact of pterygium.
  • More information about this trial is available here: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium .
  • The survey was designed with multiple-choice questions, rating questions and open-ended questions.2

Screen time can seriously harm your eyes: here’s how to avoid it

Retrieved on: 
Tuesday, February 6, 2024

The most common symptoms include irritated or itchy eyes, and a sensation of dryness or sand on the surface of the eye.

Key Points: 
  • The most common symptoms include irritated or itchy eyes, and a sensation of dryness or sand on the surface of the eye.
  • Screens are also a source of projected light, which raises the temperature of the eye’s surface and increases tear evaporation.
  • According to the data we gathered, increased screen time was linked to more severe dry eye symptoms.


Although reducing screen time is impossible in certain jobs, we can reduce irritation and problems by following certain recommendations. A basic understanding of the issue can also help us to look after our eyes.

Teardrops and eyelids

  • The eye’s surface is made up of eyelids, the tear film (the eye’s liquid coating), the cornea and the conjunctiva.
  • If any of them are affected, it can lead to irritation in the eye.
  • The eyelids are what keep the tear film evenly distributed, as well as providing protection.

Do you suffer from dry eye disease?

  • First and foremost, there is often no cause for panic: suffering certain symptoms of dry eyes does not necessarily mean you have dry eye disease.
  • A medical professional will determine whether this damage exists, and what further measures need to be taken.

How to reduce irritation and avoid dry eye disease


By taking precautions, we can ensure that screens work with us, not against us.
Screen height: It is always best to keep screens below eye level. This way the eyelids do not have to open as much, meaning less of the eye’s surface is exposed for prolonged periods.
Screen position and lighting: You should avoid light reflecting off screens, be it from a lamp or from a window behind where you sit. Excessive light forces us to concentrate harder, and therefore to blink less. This can be solved by using anti reflective filters.
Rest periods: Rest is your eyes’ best friend. A common rule of thumb is the 20-20-20 rule. For every 20 minutes of work, look at something 20 feet away (about 6 metres), for 20 seconds. This has been proven to reduce symptoms of eye dryness, as looking away from the screen re establishes our normal rate of blinking.
Environmental conditions: Low humidity, high temperatures, air currents from open windows or air conditioners, tobacco smoke and excessive air freshener can all be bad for eye health.
Eye hydration: Eye drops may be the best option on particularly intense working days. Avoid saline solutions, as their composition is not the same as the tear film. They lack the oils and proteins, and could destabilise this layer. The best option is single dose artificial tears, which do not contain preservatives and do not damage the eye.
The prevalence of screens in our society means that symptoms of dry eye disease are commonplace. If we confront this issue by taking the right steps, however, it doesn’t have to affect our quality of life.
Las personas firmantes no son asalariadas, ni consultoras, ni poseen acciones, ni reciben financiación de ninguna compañía u organización que pueda obtener beneficio de este artículo, y han declarado carecer de vínculos relevantes más allá del cargo académico citado anteriormente.

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

Retrieved on: 
Monday, January 8, 2024

This first-in-human trial of OK-101 established a clear and informed path for further development in Phase 3 registration trials.

Key Points: 
  • This first-in-human trial of OK-101 established a clear and informed path for further development in Phase 3 registration trials.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).
  • OK-101 First-In-Human trial establishes a clear clinical path for further clinical development in a Phase 3 study design using FDA recognized endpoints per the Dry Eye: Developing Drugs for Treatment Guidance for Industry.
  • A statistically significant improvement in blurred vision was also achieved at Day 29 (p = 0.01).

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023

This report provides comprehensive insights about INVELTYS for acute ocular pain (AOP) in the United States.

Key Points: 
  • This report provides comprehensive insights about INVELTYS for acute ocular pain (AOP) in the United States.
  • A detailed picture of the INVELTYS for acute ocular pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute ocular pain.
  • Further, it also consists of future market assessments inclusive of the INVELTYS market forecast analysis for acute ocular pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.
  • This report provides a detailed market assessment of INVELTYS for acute ocular pain in the United States.

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023

The "United States INVELTYS Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States INVELTYS Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about INVELTYS for acute pain in the United States.
  • A detailed picture of the INVELTYS for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute pain.
  • This report provides a detailed market assessment of INVELTYS for acute pain in the United States.

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

Retrieved on: 
Wednesday, December 6, 2023

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes.
  • A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here .
  • In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
  • Woo University is a non-profit organization committed to providing high-quality continuing education to eyecare professionals around the world.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

Retrieved on: 
Thursday, September 14, 2023

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel.
  • The product launch follows a previously announced agreement under which NovaBay was granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft under the Avenova brand.
  • The Avenova Allograft will compete in the global ophthalmology amniotic membrane market estimated at $403.6 million in 2022, which is expected to grow at 9.8% per year between 2023-2030 .
  • NovaBay’s commercial launch of Avenova Allograft includes outreach programs aimed at educating eyecare specialists on both the clinical benefits of the product, as well as the process for Medicare reimbursement.

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

Retrieved on: 
Monday, September 11, 2023

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
  • Amniotic Tissue Allograft provides a protective environment or covering for repair of the cornea and conjunctiva, helping ocular surface to return to a healthier state.
  • NovaBay intends to commercialize the prescription-only product as Avenova Allograft to leverage its Avenova eyecare brand and encourage use with other Avenova products.
  • Avenova Allograft is the only optic allograft manufactured using BioStem Technologies’ patented six-step BioREtain® process that preserves the natural integrity of the placental tissue.